Theophylline (Theophylline Anhydrous) Patent Expiration, LOE Window & CMS Spending

Theophylline (Theophylline Anhydrous) by Tris: Multi-Source Generic Molecule, 16 AB generics, $392K 2024 CMS Part D & Medicaid spend, and $1,985 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTris
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$392K
2024 Medicare Part D Spend$304K
2024 Medicaid Spend$88K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,985 intro WAC)